CompletedNot Applicable

Incidence And Outcome Of Paracentesis Induced Circulatory Dysfunction In Acute-On-Chronic Liver Failure.

India80 participantsStarted 2015-03-15

Plain-language summary

All consecutive patients admitted in ILBS from MAY 2015 to DECEMBER 2016.ACLF (Acute on chronic Liver Failure). ACLF will be randomize into Group 1: MVP (Modest Volume Paracentesis) OF Less than 5 liters with IV albumin at a dose 8 gms/L of ascitic fluid Group 2: MVP (Modest Volume Paracentesis) of Less than 5 liters without albumin

Who can participate

Age range12 Years – 75 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion criteria

✓. All patients with acute hepatic insult manifesting as jaundice (Sr. Bil. ≥ 5 mg/dL) and coagulopathy (INR≥1.5), complicated within 4 weeks by ascites and/or encephalopathy in a patient with previously diagnosed or undiagnosed chronic liver disease (ACLF) admitted in the hospital.
✓. All Cirrhotics decompensated with ascites admitted in the hospital.
✓. Grade II/III ascites
✓. Need for paracentesis.

Exclusion criteria

✕. Age \<12 or \> 75 years
✕. Hepatocellular carcinoma
✕. Non cirrhotic ascites such as malignancy or tubercular peritonitis
✕. Serum Cr \>1.5mg%
✕. Refractory septic shock
✕. Grade III/IV hepatic encephalopathy
✕. Abdominal wall cellulitis
✕. Active variceal bleed

What they're measuring

Total number of patients develop Circulatory Dysfunction because of paracentesis.

Timeframe: 1 Year

Trial details

NCT IDNCT02467348

SponsorInstitute of Liver and Biliary Sciences, India

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2017-01-31

View on ClinicalTrials.gov More Acute on Chronic Liver Failure trials